SCHEMBL160759

SCHEMBL160759

CC(C(=O)OC(C)(C)C)N1CCC(c2ncc(-c3ccc(NC(=O)Nc4ccccc4Cl)cc3)s2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 7/20 0.49
TRPV1 Q8NER1 2/20 0.40
LCK P06239 2/20 0.39
HCK P08631 2/20 0.39
SRC P12931 1/20 0.39
TEK Q02763 3/20 0.39
KIT P10721 1/20 0.39
KDR P35968 1/20 0.39
MAPK8 P45983 1/20 0.38
MAPK10 P53779 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
NPC1 O15118 1/20 0.38
TP53 P04637 1/20 0.38
RAB9A P51151 1/20 0.38
CNR1 P21554 1/20 0.38
MEN1 O00255 1/20 0.38
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38
KMT2A Q03164 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL163107 0.91 DGAT1 (0.49) DGAT1TRPV1TEKKITKDR
SCHEMBL158738 0.89 DGAT1 (0.51) DGAT1TRPV1LCKHCKSRC
SCHEMBL161173 0.89 DGAT1 (0.57) DGAT1TRPV1LCKHCKTEK
SCHEMBL165240 0.88 DGAT1 (0.51) DGAT1MEN1LMNAMAPTKMT2A
SCHEMBL160146 0.86 DGAT1 (0.49) DGAT1TRPV1KDRTRPM8
SCHEMBL161788 0.85 DGAT1 (0.50) DGAT1KDRSMN1; SMN2NPC1TP53
SCHEMBL159660 0.84 DGAT1 (0.56) DGAT1TRPV1LCKHCKSRC
SCHEMBL161574 0.83 DGAT1 (0.40) DGAT1TRPV1KDRTP53MAPT
SCHEMBL158368 0.83 DGAT1 (0.49) DGAT1LCKHCKTEKKIT
SCHEMBL162764 0.83 DGAT1 (0.51) DGAT1TEKKITKDRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2611783-A2 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS Piramal Enterprises Limited (IN) 2013-07-10 EP claimed
US-20130158075-A1 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS Piramal Enterprises Limited (IN) 2013-06-20 US claimed
WO-2012029032-A2 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2012-03-08 WO claimed
EP-2611783-A2 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS Piramal Enterprises Limited (IN) 2013-07-10 EP disclosed
US-20130158075-A1 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS Piramal Enterprises Limited (IN) 2013-06-20 US disclosed
WO-2012029032-A2 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158075-A1 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS DGAT1, DGAT2, SOAT1 DGAT1 1/4885TRPV1 2426/4885LCK 2899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.